Business Context and Reporting Period
This Form 6-K filing by XORTX Therapeutics Inc. covers the month of September 2026, with a report date of September 4, 2026. The filing details the re-engagement of IR Agency LLC for investor relations and marketing services following the Company's voluntary delisting from the TSX Venture Exchange (TSXV), which became effective on September 1, 2026. The Company remains listed on the Nasdaq Capital Market under the symbol "XRTX."
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the investor relations agreement:
- Agreement Fee: US$2,500,000 payable in advance to IR Agency LLC.
- Funding Source: The fee is funded from amounts previously paid to IR Agency and returned to the Company in August 2026 after the termination of the original agreement.
- Payment Terms: The fee is fully earned upon receipt and is non-refundable.
Material Changes
The primary material change reported is the execution of a new consulting agreement with IR Agency LLC on September 2, 2026. This follows the termination of a prior agreement in August 2026, during which the Company received a full refund of US$2,500,000. The new agreement redeploys these funds for a three-month marketing and advertising program commencing September 3, 2026.
Guidance, Outlook, and Risks
Management intends to utilize the new IR Agreement to communicate with the financial community through up to ten news distribution campaigns. The filing includes forward-looking statements regarding the anticipated benefits of the TSXV delisting and the success of the investor relations program. Key risks identified include:
- The investor relations program may not achieve its intended objectives.
- Ongoing compliance with Nasdaq continued listing standards.
- The Company's need for additional capital.
Investor Verification Checklist
- Verify the Company's continued compliance with Nasdaq Capital Market listing standards post-delisting from TSXV.
- Confirm the utilization of the US$2,500,000 re-engagement fee and the specific deliverables of the IR Agency LLC contract.
- Review the Company's cash position to assess its ability to fund operations and potential future capital needs.
- Monitor the effectiveness of the marketing campaigns in achieving the Company's strategic objectives.